Printed From:

Now Available

SOLIQUA 100/33

A combination of Lantus® and lixisenatide, a GLP-1 receptor agonist, in a once-daily injection

For your adult patients with type 2 diabetes uncontrolled on Lantus®
Demonstrated HbA1c reduction vs Lantus® and safety profile
See Clinical Data
Get your patients started
See How
Eligible patients pay $0*
Learn More